News
Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...
Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main ...
The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...
Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback